Skip to main content

Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study With Sabarish Ayyappan, MD

Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 study which investigated odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).   Oncology...

Continue reading

Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL With Jon Arnason, MD

Oncology Data Advisor® · Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL: Jon Arnason, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Jon Arnason, MD, a Lymphoma Clinical Trial Specialist at Beth Israel Deaconess Medical Center, to discuss his abstract and presentation regarding the ELM-2 trial which studied circulating tumor DNA (ctDNA) as a predictive biomarker with odronextamab for follicular lymphoma (F...

Continue reading

Maintaining Functioning and Quality of Life With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD

Oncology Data Advisor® · Maintaining Functioning and QOL With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss the results from the ELM-2 study in which the efficacy of odronextamab was investigated for maintaining functionality and quality of life in patients ...

Continue reading

Exploring Epcoritamab for Relapsed/Refractory Follicular Lymphoma With Dr. Matthew Hadfield, Dr. Alankrita Taneja, Dr. Tahi Ahmadi, and Dr. Jacqueline Nielsen

Recently, Genmab and AbbVie announced updated results of the phase 1/2 EPCORE™ NHL-1 clinical trial of epcoritamab (epco) for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Matthew Hadfield and Dr. Alankrita Taneja of the Oncology Data Advisor Fellows Forum speak with Dr. Tahi Ahmadi, Chief Medical Officer at Genmab, and Dr. Jacqueline Nielsen, Therapeutic Area Head for Hematology at AbbVie, about the significance of these results, the benefits of epcoritamab's subcutaneous administration, management of adverse events, and the future role of epcoritamab in the treatment landscape for follicular lymphoma.  

Continue reading

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.  

Continue reading

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.  

Continue reading

Mosunetuzumab-axgb Approved for Relapsed/Refractory Follicular Lymphoma

The FDA has granted accelerated approval to mosunetuzumab-axgb (Lunsumio™, Genentech) for adult patients with relapsed or refractory follicular lymphoma (FL) who have previously received at least two lines of systemic therapy. "Mosunetuzumab is a CD20 x CD3 T-cell–engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells," wrote L. Elizabeth Budde, MD, PhD, Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of ...

Continue reading

Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular Lymphoma

A learning opportunity provided by i3 Health has demonstrated significant knowledge gains and proficiency regarding the optimization of treating patients with relapsed/refractory (R/R) follicular lymphoma (FL). Non-Hodgkin lymphoma is one of the most prevalent cancers in the United States, with a 2022 estimate of around 80,470 people to be diagnosed, with 20,250 of these cases expected to be fatal. One in five of these cases will be FL, which is usually a slow-growing lymphoma but has the chance...

Continue reading

Umbralisib Withdrawn for Marginal Zone Lymphoma and Follicular Lymphoma

The FDA has announced that it has withdrawn its approval of umbralisib (Ukoniq®, TG Therapeutics) for treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib had previously been granted accelerated approval in February 2021 based on the UNITY-NHL trial (NCT02793583). The withdrawal of this treatment was determined due to updated data from the UNITY-CLL trial (NCT02612311), which revealed a possible increased risk of death in patients receiving umbralisib. TG Therapeuti...

Continue reading

Accelerated Approval Granted to Tisagenlecleucel for Treatment of Relapsed or Refractory Follicular Lymphoma

The FDA has given accelerated approval to tisagenlecleucel (Kymriah®, Novartis) for treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) within six months of receiving two or more lines of systemic therapy or if the patient relapsed after an autologous hematopoietic stem cell transplant. "Follicular lymphoma is a common non-Hodgkin lymphoma that is generally considered indolent, but the disease remains incurable, and the majority of patients eventually relapse," wrote...

Continue reading

Personalized Care Plans for Patients With Relapsed/Refractory Follicular Lymphoma: Dr. Loretta J. Nastoupil, MD

Follicular lymphoma is a disease that affects 2.7 per 100,000 individuals each year, with a five-year survival rate of 89.7%. It is the most common subtype of indolent non-Hodgkin's lymphoma; about 22% of newly diagnosed non-Hodgkin lymphoma cases are follicular lymphoma. The development of novel therapies offers new treatment options for patients living with follicular lymphoma. In this interview, Dr. Loretta J. Nastoupil, MD, Section Chief of New Drug Development in the Department of Lymphoma/...

Continue reading

Educational Needs in the Management of Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...

Continue reading

FDA Approves Axicabtagene Ciloleucel for Relapsed/Refractory Follicular Lymphoma

The FDA has granted accelerated approval to axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. An indolent form of non-Hodgkin lymphoma (NHL) that is not generally curable, FL is considered a chronic disease. Therefore, people living with FL often require second-line therapies after their di...

Continue reading

Follicular Lymphoma: Hard to Improve on Bendamustine/Rituximab Induction

The latest data from the three-arm randomized phase 2 ECOG-ACRIN E2408 trial, which sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL), have yielded disappointing results: neither adding bortezomib to BR induction nor adding lenalidomide following BR induction improves outcomes. For the trial, 289 patients were randomized to receive either BR induction followed by two-year rituximab main...

Continue reading

Tazemetostat for Follicular Lymphoma Granted Accelerated Approval

Tazemetostat (TAZVERIK™, Epizyme, Inc.) has been approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have tumors that are positive for an EZH2 mutation, have received at least 2 previous systemic therapies, and have no satisfactory alternative treatment options. In addition, the FDA approved the cobas® EZH2 Mutation Test (Roche Molecular Systems, Inc.) as a companion diagnostic for tazemetostat. An EZH2 inhibitor, tazemetostat has previously been approved f...

Continue reading